1991年5月以来,我们采用蝮蛇抗栓酶3号治疗慢性肺原性心肌病(下称肺心病)100例,经与同期常规治疗的100例比较,疗效显著。1.临床资料:两组肺心病患者均按1977年第二次全国肺心病会议制订的标准诊断。治疗组男61例,女39例;年龄31～70岁。对照组患者的年龄、发病特点、疗程、症状及体征与治疗组无显著性差异。 Since May 1991, we use viper antithrombin enzyme 3 treatment of chronic pulmonary cardiomyopathy (hereinafter referred to as pulmonary heart disease) 100 cases, compared with the routine treatment of 100 cases over the same period, the curative effect is significant. 1. Clinical data: two groups of patients with pulmonary heart disease were diagnosed in accordance with the standard set by the Second National Conference of Cor Pulmonale in 1977. Treatment group, 61 males and 39 females; aged 31 to 70 years. There was no significant difference in the age, onset characteristics, course of treatment, symptoms and signs between the control group and the treatment group.